SESSION TITLE: Asthma and Comorbid Disease SESSION TYPE: Original Investigations PRESENTED ON: 10/10/2018 08:45 AM - 09:45 AM PURPOSE: Patients with severe eosinophilic asthma have a greater risk for exacerbations and emergency department visits. Comorbidities have been associated with worse outcomes. We sought to establish whether patients with greater baseline eosinophil counts had differences in comorbidities at baseline. METHODS: This was a post-hoc analysis of pooled data from the Phase III SIROCCO (NCT01928771; Lancet 2016;388:2115–27) and CALIMA (NCT01914757; Lancet 2016;388:2128–41) trials. Patients were aged ≥12 years with severe, uncontrolled asthma with two or more prior exacerbations in the year before enrollment and were taking medium- or high-dosage inhaled corticosteroids and long-acting β2-agonists. Baseline comorbidities were assessed for patients with blood eosinophil counts ≥300 (n=1,684) and <300 cells/μL (n=826). RESULTS: Overall, baseline comorbidities were similar between patients with blood eosinophil counts ≥300 and <300 cells/μL. A greater percentage of patients with ≥300 cells/μL, compared with those with <300 cells/μL, had nasal polyps (20.9% vs. 9.9%) and sinusitis (25.7% vs. 20.2%). The most frequent comorbidities in both groups were hypertension (≥300: 30.7%, <300: 37.0%), gastrointestinal reflux (≥300: 23.9%, <300: 25.2%), hypercholesterolemia (≥300: 11.9%, <300: 14.8%), atopic dermatitis (≥300: 12.2%, <300: 11.1%), obesity (≥300: 9.2%, <300: 13.8%), and diabetes (≥300: 9.1%, <300: 13.6%). CONCLUSIONS: Patients with greater baseline eosinophils appear to have had a greater incidence of nasal polyps. Other comorbidities did not appear to be present with greater frequency in these patients. Study inclusion and exclusion criteria may have influenced the comorbidities observed for both groups. CLINICAL IMPLICATIONS: The presence of nasal polyps could potentially be used as a marker of increased blood eosinophils in patients with severe, uncontrolled asthma and may be helpful in guiding clinical decisions on the use of benralizumab. DISCLOSURES: No relevant relationships by Eugene Bleecker, source=Web Response Advisory relationship with Astra Zeneca Please note: $1-$1000 Added 03/02/2018 by J. Mark FitzGerald, source=Admin input, value=0 Peer reviewed funding relationship with Astra Zeneca Please note: $1-$1000 Added 03/02/2018 by J. Mark FitzGerald, source=Admin input, value=Grant/Research Support Speaker/Speaker's Bureau relationship with Astra Zeneca Please note: $1-$1000 Added 03/02/2018 by J. Mark FitzGerald, source=Admin input, value=Honoraria Advisory Committee Member relationship with GSK Please note: $1-$1000 Added 03/02/2018 by J. Mark FitzGerald, source=Admin input, value=0 0 relationship with GSK Please note: $1-$1000 Added 03/02/2018 by J. Mark FitzGerald, source=Admin input, value=Grant/Research Advisory Committee Member relationship with BI Please note: $1-$1000 Added 03/02/2018 by J. Mark FitzGerald, source=Admin input, value=0 Speaker/Speaker's Bureau relationship with BI Please note: $1-$1000 Added 03/02/2018 by J. Mark FitzGerald, source=Admin input, value=Honoraria Advisory Committee Member relationship with Novartis Please note: $1-$1000 Added 03/02/2018 by J. Mark FitzGerald, source=Admin input, value=0 Advisory Committee Member relationship with TEVA Please note: $1-$1000 Added 03/02/2018 by J. Mark FitzGerald, source=Admin input, value=0 Advisory Committee Member relationship with Pfizer Please note: $1-$1000 Added 03/02/2018 by J. Mark FitzGerald, source=Admin input, value=0 Advisory Committee Member relationship with Sanofi Regeneron Please note: $1-$1000 Added 03/02/2018 by J. Mark FitzGerald, source=Admin input, value=0 0 relationship with Amgen Please note: $1-$1000 Added 03/02/2018 by J. Mark FitzGerald, source=Admin input, value=Grant/Research Support 0 relationship with Johnson and Johnson Please note: $1-$1000 Added 03/02/2018 by J. Mark FitzGerald, source=Admin input, value=Grant/Research Support 0 relationship with Sanofi Novartis Please note: $1-$1000 Added 03/02/2018 by J. Mark FitzGerald, source=Admin input, value=Grant/Research Support Speaker/Speaker's Bureau relationship with Novartis Please note: $1-$1000 Added 03/02/2018 by J. Mark FitzGerald, source=Admin input, value=Honoraria Speaker/Speaker's Bureau relationship with Pfizer Please note: $1-$1000 Added 03/02/2018 by J. Mark FitzGerald, source=Admin input, value=Honoraria Speaker/Speaker's Bureau relationship with Merk Please note: $1-$1000 Added 03/02/2018 by J. Mark FitzGerald, source=Admin input, value=Honoraria No relevant relationships Added 02/27/2018 by Ubaldo Martin, source=Web Response, value=Salary Removed 05/10/2018 by Ubaldo Martin, source=Web Response Employee relationship with AstraZeneca Please note: >$100000 Added 02/28/2018 by Sarang Rastogi, source=Web Response, value=Salary Employee relationship with AstraZeneca Please note: >$100000 Added 02/26/2018 by Frank Trudo, source=Web Response, value=Salary